BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25326394)

  • 1. Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis.
    Hsu CY; Liu PH; Lee YH; Hsia CY; Huang YH; Chiou YY; Tsai YJ; Nagaria TS; Huo TI
    Ann Surg Oncol; 2015 Apr; 22(4):1324-31. PubMed ID: 25326394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4: A Propensity Score Analysis.
    Hsu CY; Liu PH; Lee YH; Hsia CY; Huang YH; Tsai YJ; Nagaria TS; Lin HC; Huo TI
    J Clin Gastroenterol; 2015; 49(10):878-84. PubMed ID: 25710525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma.
    Hsu CY; Liu PH; Ho SY; Hsia CY; Kudaravalli P; Lee YH; Chiou YY; Tsai YJ; Huang YH; Huo TI
    BMC Cancer; 2018 Mar; 18(1):289. PubMed ID: 29540157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
    Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
    Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria.
    Liu PH; Lee YH; Hsu CY; Huang YH; Chiou YY; Lin HC; Huo TI
    Ann Surg Oncol; 2014 Nov; 21(12):3835-43. PubMed ID: 24903236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
    Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI
    J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Apr; 27(4):690-9. PubMed ID: 22436058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis.
    Zhu SL; Ke Y; Peng YC; Ma L; Li H; Li LQ; Zhong JH
    PLoS One; 2014; 9(12):e115834. PubMed ID: 25541684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System.
    Hsu CY; Liu PH; Lee YH; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
    Medicine (Baltimore); 2015 Jul; 94(29):e1223. PubMed ID: 26200647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Pai JT; Loong CC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    Ann Surg Oncol; 2012 Mar; 19(3):842-9. PubMed ID: 21913008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages.
    D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Marti P; Bilbao JI; Martinez-Cuesta A; Benito A; Alegre F; Mauleón E; Herrero JI; Quiroga J; Prieto J; Sangro B
    Ann Surg Oncol; 2011 Jul; 18(7):1964-71. PubMed ID: 21267791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases.
    Aziz AO; Omran D; Nabeel MM; Elbaz TM; Abdelmaksoud AH; Attar IE; Shousha HI
    Asian Pac J Cancer Prev; 2016; 17(5):2539-43. PubMed ID: 27268626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison liver resection with transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma patients on long-term survival after SPSS propensity score matching].
    Ke Y; Zhong J; Guo Z; Liang Y; Li L; Xiang B
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):747-50. PubMed ID: 24844957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities.
    Ho CM; Lee PH; Shau WY; Ho MC; Wu YM; Hu RH
    Surgery; 2012 May; 151(5):700-9. PubMed ID: 22284764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system.
    Hsu CY; Lee YH; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Lee FY; Huo TI
    Hepatology; 2013 Jan; 57(1):112-9. PubMed ID: 22806819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
    Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria.
    Hsu CY; Lee YH; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Lee FY; Huo TI
    Ann Surg Oncol; 2013 Jun; 20(6):2035-42. PubMed ID: 23306955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study.
    Espinosa W; Liu YW; Wang CC; Lin CC; Wang JH; Lu SN; Hung CH
    J Formos Med Assoc; 2018 Mar; 117(3):197-203. PubMed ID: 28411877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing trends in long-term outcomes after hepatic resection for hepatocellular carcinoma: A 30-year, single-center experience.
    Yamamoto Y; Ikoma H; Morimura R; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    Anticancer Res; 2013 Nov; 33(11):5097-105. PubMed ID: 24222155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.